[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.179.232. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 1996

Corticosteroid Therapy of Eye DiseaseFifty Years Later

Author Affiliations

Boston, Mass

Arch Ophthalmol. 1996;114(8):1000-1001. doi:10.1001/archopht.1996.01100140208016
Abstract

It IS HARD TO IMAGINE the practice of ophthalmology without corticosteroids. Fifty years ago the treatment options for uveitis included atropine drops, oral salicylates, direct application of heat to the eye, and induction of fever with typhoid vaccine or other proteins. Then, in 1949, Hench and associates1 described the beneficial effects of adrenocorticotropic hormone (ACTH) and cortisone in the treatment of rheumatoid arthritis. Within months of this seminal article it was clear that these drugs could help control ocular inflammation, and case reports began to appear. To read these articles is to share in the excitement and promise of a new era.

In 1949, Elkinton and associates2 described improvement of hemorrhagic retinopathy in a patient treated with ACTH for "generalized collagen disease." Three separate reports soon followed. Mann and Markson3 successfully controlled a patient's uveitis and episcleritis with ACTH therapy. Gordon and McLean4 described transient improvement

First Page Preview View Large
First page PDF preview
First page PDF preview
×